Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1218 Features
eHealth News Roundup for April 21st – May 2nd 2003

09 May 03

The healthcare industry has utilized the Internet most recently as both a marketing tool and as a facility to pass on important medical information. Leading drug maker Abbott Laboratories will be look
Michael Randle

Behavioral Disorders: ADHD and beyond

09 May 03

Over the past decade, behavioral disorders have received increasing attention, both from the media and medical professionals, however only attention deficit/hyperactivity disorder has emerged as a key
Michael Randle

Introducing EIM: The key to improving pharmaceutic

08 May 03

Enterprise Incentive Management (EIM) software -improves pharmaceutical sales and provides accurate and timely compensation to both direct and indirect sales people. Already used in the pharmaceutica
David Blume

Biotechnology and the Revitalisation of Drug Devel

02 May 03

The development of novel medicines is critical if diseases and disorders are to be effectively treated. As a result, many have looked to biotechnology to provide continuing innovation in the field of
Pietro Bonacossa and Dr Faiz Kermani

Risk and Reward in R&D

02 May 03

Investing in R&D requires long-term planning and the willingness to take risks. Only about 15% of new drugs entering development subsequently reach the market, and the overall expense can be in the or
Faiz Kermaini & Pietro Bonacossa

Asthma Therapeutics: New treatment options and eme

02 May 03

Asthma drives a large but competitive market. Current therapeutics are generally effective but patient compliance is often poor. Future commercial successes in the asthma arena will likely focus on mo
LeadDiscovery/Prof. Peter Barnes

HIV: Justifying premium pricing

01 May 03

Roche's recent announcement of an EU price point of $20,570 per year for its novel HIV fusion inhibitor Fuzeon has brought the issue of pricing HIV therapies to the fore. Roche's premium pricing strat
Michael Randle

Malaria: The Neglected Disease

30 Apr 03

Malaria kills more people in the world than any other communicable disease except tuberculosis, yet in terms of new drug development the disease is widely seen as a neglected one.
Dr Faiz Kermani

MAPK/ERK-kinase inhibition as a promising strategy

26 Apr 03

Approximately 9% of the US population suffers from moderate to severe non-cancer-related pain, a figure that includes 40-70 million individuals with chronic pain. The development of analgesics represe
LeadDiscovery

Target of the Month, TherapeuticAdvances, April, 2

20 Apr 03

Considerable evidence exists linking the retinoids to amyloid expression and neural responses to amyloid. Retinoic acid derivative may thus offer a therapeutic avenue for Alzheimer's disease
LeadDiscovery

eHealth News Roundup for April 7th – 17th 2003 fro

17 Apr 03

While the Internet continued to be used for important reference and record keeping purposes, its power as a communications medium was perhaps most evident by the websites being set up to help those wo
Michael Randle

Bone metastases: Zometa to become the gold-standar

16 Apr 03

Ever since receiving FDA approval for Aredia in September 1998 Novartis has held the gold standard treatment for bone metastases. In Zometa the Swiss pharmaceutical company possesses a more potent, ne
Michael Randle

Using the Internet: Can Pharmaceutical companies a

07 Apr 03

The considerable investment and overheads required for the development of new drugs mean that pharmaceutical companies must establish brand loyalty throughout a product’s lifecycle in order to protect
Michael Randle

eHealth News Roundup for 21st March – 4th April, 2

07 Apr 03

Physicians, patients and even healthcare companies were equally well catered for by a number of important eHealth announcements that came to light in the past fortnight. The prospect of remote medical
Michael Randle

ICON takes further step towards major player statu

04 Apr 03

The growth of outsourced clinical research for the pharmaceutical industry appears to know no bounds, the latest expansion of a pharmiweb client happened in early February when ICON, the global clinic
Mark Stacey

Therapeutic & pharmaceutical opportunities for ost

28 Mar 03

In anticipation of the launch of Forteo, LeadDiscovery in collaboration with field-leader, Cees Vermeer have produced a state of the art report on both the field of osteoprosis in general and also mor
LeadDiscovery

PHARMIWEB SOAPBOX: Marketing Regulations – Is Onli

27 Mar 03

According to all pharmaceutical regulatory authorities of note, the regulations that apply to offline sales and marketing activity in the industry should also apply to all such activity in the online
Colin Williams

Schering-Plough: facing the challenges of blockbus

24 Mar 03

With the recent patent expiry of Claritin, a drug that netted Schering-Plough some $5 billion in sales in 2001-2002, the antihistamine market will soon be flooded by a raft of cheap generic copies of
Michael Randle

Natural bioactive compounds as therapeutic candida

20 Mar 03

Benign prostatic hypertrophy (BPH) is very common in men aged 50 years and older. Resultant bladder hyperactivity leads to self-enforced changes in life style, increased frequency of falls in the immo
LeadDiscovery

COX-II Inhibitors: Looking to drive market growth

20 Mar 03

With over $6 billion in sales in 2002, COX-II inhibitors are dominating the market for NSAIDs at a global level. These drugs have however, struggled to make an impact outside the US. With their long-t
Michael Randle

Rheumatoid Arthritis: Abbott looking for a greater

13 Mar 03

In rheumatoid arthritis treatment a shift towards the earlier use of DMARDs has threatened the dominance of the NSAID class of drugs. This has opened up considerable opportunity for drugs such as Remi
Michael Randle

Clinical Trials in Spain – An Update

13 Mar 03

Would you do a clinical study in Spain? The immediate reaction of the majority of the international clinical research community is “maybe but only at the later stages (Phase III-b, Phase IV)”. Spain i
Lewis Cameron

5-HT7 antagonists: Novel molecules for the unmet m

11 Mar 03

Due to the high incidence of migraine and its effect on quality of life the highly competitive triptan market exceeds of $2 billion in global sales. Triptans aborting a migraine attack once it has sta
LeadDiscovery

Retinoids : An A-Z guide to their biology, therape

28 Feb 03

Retinoids play a key role in differentiation, proliferation and apoptosis. As a result over 30 analogs of retinoic acid are now either in development or on the market. Retinoids in current use are eff
LeadDiscovery

Pfizer/Pharmacia: Moving the goalposts

26 Feb 03

The proposed merger between Pfizer and Pharmacia will create a company with total ethical sales twice those of its nearest competitor. Declining R&D productivity, and a flood of patent expirations hav
Michael Randle

Patients Wanted: Communication, Marketing and Tech

26 Feb 03

The process of finding, screening, and recruiting clinical trial patients at multiple research sites is a challenge for even the largest pharmaceutical sponsors and clinical research organizations.
Dr Faiz Kermani

Advertising